However, inactivated NF2 could serve as a bypass mechanism to confer resistance to targeted therapies for lung cancers, including osimertinib, erlotinib, afatinib, and MET TKIs [33, 55, 56, 57]. Here, NF2 is linked to lung carcinoma.